NZ606541A - Anti-cmet antibody - Google Patents

Anti-cmet antibody

Info

Publication number
NZ606541A
NZ606541A NZ606541A NZ60654109A NZ606541A NZ 606541 A NZ606541 A NZ 606541A NZ 606541 A NZ606541 A NZ 606541A NZ 60654109 A NZ60654109 A NZ 60654109A NZ 606541 A NZ606541 A NZ 606541A
Authority
NZ
New Zealand
Prior art keywords
cdr
nos
amino acid
antibody
acid sequences
Prior art date
Application number
NZ606541A
Inventor
Thierry Wurch
Cedric Bes
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Priority claimed from NZ593853A external-priority patent/NZ593853A/en
Publication of NZ606541A publication Critical patent/NZ606541A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is an isolated monoclonal antibody, or a divalent functional fragment or derivative thereof, capable to inhibit the c-Met dimerization, said antibody comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with respectively 5 the amino acid sequences SEQ ID Nos. 1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with respectively the amino acid sequences SEQ ID Nos. 5, 6 and 7, wherein said antibody comprises a hinge region comprising an amino acid sequence selected from the group consisting of SEQ ID Nos. 59 to 63 and 66 to 70.
NZ606541A 2008-12-02 2009-12-02 Anti-cmet antibody NZ606541A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08875957 2008-12-02
US18450209P 2009-06-05 2009-06-05
NZ593853A NZ593853A (en) 2008-12-02 2009-12-02 ANTI-cMET ANTIBODY

Publications (1)

Publication Number Publication Date
NZ606541A true NZ606541A (en) 2014-10-31

Family

ID=50624332

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ603292A NZ603292A (en) 2008-12-02 2009-12-02 Anti-cmet antibody
NZ606541A NZ606541A (en) 2008-12-02 2009-12-02 Anti-cmet antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ603292A NZ603292A (en) 2008-12-02 2009-12-02 Anti-cmet antibody

Country Status (1)

Country Link
NZ (2) NZ603292A (en)

Also Published As

Publication number Publication date
NZ603292A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
NZ593853A (en) ANTI-cMET ANTIBODY
NZ599958A (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
NZ596837A (en) Anti-vegf antibodies and their uses
RS52919B (en) Sclerostin binding agents
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
NZ596042A (en) Humanized anti-factor d antibodies
UA108466C2 (en) Antibody antagonises c-Met
NZ585559A (en) Humanized antibodies against tl1a
NZ705653A (en) Novel antibody for the diagnosis and/or prognosis of cancer
NZ599144A (en) Interleukin -13 binding proteins
WO2006103100A3 (en) Antibodies against ccr5 and uses thereof
NZ603045A (en) Tnf-alpha binding proteins
NZ599761A (en) Engineered anti-tslp antibody
NZ599779A (en) Compositions and methods for treating inflammatory disorders
NZ605980A (en) Anti-fap antibodies and methods of use
NZ595687A (en) Anti-tnf-alpha antibodies and their uses
RS53405B (en) Humanized anti cxcr4 antibodies for the treatment of cancer
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ596992A (en) Il-12/p40 binding proteins
AR080243A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
NZ610153A (en) Novel anti-dr5 antibody
RU2012154339A (en) NEW ANTI-BODY AGAINST c-Met
NZ712765A (en) Antibodies that bind csf1r
RU2602878C3 (en) CONJUGATES "KALYCHEAMICIN DERIVATIVE-CARRIER"

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 DEC 2016 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20150219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2017 BY ACUMASS

Effective date: 20161122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2018 BY ACUMASS

Effective date: 20171123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2019 BY ACUMASS

Effective date: 20181119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2020 BY ACUMASS

Effective date: 20191120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2021 BY ACUMASS

Effective date: 20201118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2022 BY ACUMASS

Effective date: 20211122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2023 BY ACUMASS

Effective date: 20221118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2024 BY ACUMASS

Effective date: 20231121